drugset / Trial / NCT00752206
A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
Phase 2
Terminated
38 enrolled
Sarcoma Alliance for Research through Collaboration
AstraZeneca · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine how long patients who undergo complete surgical removal of recurrent osteosarcoma in the lung will remain free of cancer after taking Saracatinib compared to patients taking placebo (a sugar pill).
Timeline
- Start
- 2009-03
- Primary completion
- 2017-08
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | saracatinib | Small molecule | 175 mg | Oral |